Demonstration of the feasibility of closed loop control of blood glucose in the intensive care unit setting using a novel artificial intelligence based glucose control system
Active Project Grant Awarded Last action
- Award ID
- R44DK133084
- Recipient
-
Ideal Medical Technologies Inc. UEI MNZYR2BKY8T4
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,847,488
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date 88% complete
- Originally
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Failure to achieve tight glucose control in intensive care unit (ICU) patients is a major cause of morbidity and mortality. The current method for controlling glucose for the almost 6 million patients admitted to the ICU each year consists of time-intensive, error-prone, manual processes in which nurses have to check patient glucose levels, calculate dosing and rates for intravenous (IV) insulin, and adjust IV pumps. These steps can decrease nursing efficiency by up to 2 hours per patient per day. Ideal medical technologies is developing an improved system for glucose control in ICU patients. Fusiontm, our closed-loop glucose control system, acts as an artificial pancreas; our innovation centers on using biomimicry to design our artificial intelligence-based algorithms so that they function like the glucose regulation system natively present in humans. These algorithms allow fusion to continuously monitor a patient's blood glucose level and autonomously infuse insulin and/or dextrose into the patient to maintain the blood glucose level within a physician-prescribed range. An automated, closed-loop approach to regulating glucose in critically ILL patients would represent a paradigm shift in treatment protocols, and ultimately, morbidity and mortality rates in the ICU. One potential additional benefit of a closed-loop glucose control system beyond improved patient outcomes is the possibility of decreasing nursing time spent on glucose control. The FDA designated fusion as a breakthrough medical device in 2019, and our original IDE application was approved by the FDA as of this year. In this proposed project, we intend to optimize a commercial fusion system and test IT first in a 10-person non-randomized clinical safety trial and then in a 30-person randomized controlled safety and efficacy trial - both trials will be performed in an ICU at emory university. Successful completion of this project will demonstrate clinical safety and preliminary efficacy of the fusion closed-loop glucose control system and will enable US to then move into larger efficacy phase III trials in a subsequent stage of development and commercialization; these phase III trials will complete our data package for the FDA for marketing approval.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $931,064 | |
| Amendment | $958,212 | |
| Original award | $958,212 |
Quick answers
Who received award R44DK133084?
R44DK133084 was awarded to Ideal Medical Technologies Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on June 1, 2022.
How much is award R44DK133084 worth?
$2,847,488 has been obligated on R44DK133084.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award